Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Tuesday, February 9, 2010, 11:29pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
Hemobiotech Inc. (HMBT.OB)
At 14:56 EST:
0.35 USD
0.00 (0.00%)
MORE ON HMBT.OB
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
HEMOBIOTECH INC
(OTC BB:HMBT.OB) Delayed quote data
Last Trade:
0.35 USD
Trade Time:
2:56PM EST
Change:
0.00 (0.00%)
Prev Close:
0.35
Open:
0.22
Bid:
0.25
x 5000
Ask:
0.35
x 5000
1y Target Est:
N/A
Day's Range:
0.22 - 0.35
52wk Range:
0.15 - 1.01
Volume:
8,051
Avg Vol
(3m)
:
3,106.35
Market Cap:
7.14M
P/E
(ttm)
:
N/A
EPS
(ttm)
:
-0.21
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
Add HMBT.OB to Portfolio
Download Data
HEADLINES
HEMOBIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online
(Wed, Jan 6)
HEMOBIOTECH, INC. Financials
EDGAR Online Financials
(Thu, Dec 10)
HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Thu, Dec 3)
HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Thu, Dec 3)
HEMOBIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online
(Thu, Oct 29)
HEMOBIOTECH, INC. Financials
EDGAR Online Financials
(Thu, Aug 27)
HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Tue, Aug 18)
HEMOBIOTECH, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online
(Tue, Aug 18)
HemoBioTech Gains Congressional Recognition of Its Blood Substitute Technology
Marketwire
(Mon, Aug 17)
HemoBioTech to Present "Need for Blood Substitute to Prevent HIV Transmission" at 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
Marketwire
(Tue, Jun 2)
More Headlines for HMBT.OB...
BUSINESS SUMMARY
HemoBioTech, Inc., a development stage biopharmaceutical company, engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Science Center School of Medicine (TTUHSC) in Texas.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices